Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Myeloproliferative Disorders

PHCHBS-WD4070, NCT00718263: Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

	In 2nd line CML chronic phase pts
	Feb 2014 - Feb 2014: In 2nd line CML chronic phase pts

Active, not recruiting

Japan, US, Europe, RoW

Nilotinib, Imatinib

Novartis Pharmaceuticals

Myelogenous Leukemia, Chronic

10/18

NCT00066300: Allogeneic Peripheral Stem Cell Transplantation Followed By Donor Lymphocyte Infusions in Treating Patients With Hematologic Cancer

Active, not recruiting

graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy

National Heart, Lung, and Blood Institute (NHLBI)

Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

NCT00005846: Tipifarnib in Treating Patients With Myeloproliferative Disorders

Active, not recruiting

1/2

tipifarnib

Stanford University, National Cancer Institute (NCI)

Leukemia, Myelodysplastic/Myeloproliferative Neoplasms

NCT00302016 / 2005-001818-41: Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

No Longer Available

N/A

US, Canada, Europe, RoW

AMN107

Novartis Pharmaceuticals

Chronic Myeloid Leukemia

11/08

NCT00854841: The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

Available

N/A

RoW

Dasatinib and Imatinib, Sprycel and Gliveec

Pusan National University Hospital

Chronic Myeloid Leukemia

NCT00413270: Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

No Longer Available

N/A

Canada

nilotinib

Novartis Pharmaceuticals

Chronic Myelogenous Leukemia

NCT01549548: Compassionate Use Ponatinib

No Longer Available

N/A

Ponatinib, AP24534

OHSU Knight Cancer Institute, Ariad Pharmaceuticals

Philadelphia Chromosome Positive (Ph+) Leukemias, Chronic Myeloid Leukemia

NCT00423826: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

No Longer Available

N/A

Busulfan, Busulfex®, Myleran®, Cytarabine, DepoCyt(TM), Liposomal Ara-C, Fludarabine phosphate, Fludara, mycophenolate mofetil, Cellcept, tacrolimus, Advagraf, Prograf, Protopic, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation

Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)

Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis

01/15

HEMATO-BIO, NCT02320656: Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders--IPC-2013-015

Recruiting

N/A

650

Europe

Blood sampling, Bone marrow aspirate, Skin biopsy, Buccal swab

Institut Paoli-Calmettes

Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

05/19

05/24



	Diseases Companies Products Productz Mechanisms of Action Sites